# Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

Study · id `cardio:ct-nct05612035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05612035](<https://clinicaltrials.gov/study/NCT05612035>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05612035

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 129 participants.

## Technical summary

Registry record NCT05612035. Randomized; triple masking; primary purpose treatment. Start 2023-03-16 (actual); primary completion 2026-04-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT05612035, source copy `cardio:ctgov-nct05612035-2026-11-13`, retrieved 2026-11-18)
- Started: 2023-03-16 (actual) (ClinicalTrials.gov record NCT05612035, source copy `cardio:ctgov-nct05612035-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2026-04-09 (actual) (ClinicalTrials.gov record NCT05612035, source copy `cardio:ctgov-nct05612035-2026-11-13`, retrieved 2026-11-18)
- Completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT05612035, source copy `cardio:ctgov-nct05612035-2026-11-13`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Colombia; France; Germany; Guatemala; Israel; Italy; Mexico; Peru; South Africa; South Korea; Spain; Switzerland; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05612035, source copy `cardio:ctgov-nct05612035-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05612035-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
- Condition: Pulmonary Hypertension
- Condition: Chronic Obstructive Pulmonary Disease
- Intervention (Drug): Frespaciguat
- Intervention (Drug): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 4fd35fdfe062b980672977aaa855570255f812f91280c0a00f4ed85dfbdf98ca
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
